Moreover, CXCR3, which is the corresponding receptor of Cxcl9 and Cxcl10, is expressed by stem-like CD8+ Tpex cells and functions in CD8+ T-cell migration and positioning within tumors, as reported by prior studies43,47–49, was significantly upregulated in CD8+ T cells after LDRT treatment of tumor (Fig. 5h, Supplementary Fig. 10l). Here, CXCL9 is linked to neoplasm.